ASCO GI 2021 | ARC-8: AB680 + zimberelimab for first-line mPDAC

Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, provides an update on the ARC-8 trial (NCT04104672), a Phase I/Ib study to evaluate the safety and tolerability of AB680, a potent and selective inhibitor of CD73, plus chemotherapy and zimberelimab, an anti-PD-1 antibody, in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).